NYSE:TEVA   Teva Pharmaceutical Industries Limited
TEVA has been a repair story now for many years. With litigation in the process of being resolved, debt burdens of $2 bn. per year appear manageable with cash flow - TEVA is moving away from a debt/litigation story
to an equity story. Cash Flow of $3bn + per year, Net Income of ~ 2bn.+.... warrant a blended Intrinsic Value of ~ $22 per share. TEVA's technicals show a textbook double bottom with positive divergence. Reverting to trends and fibonacci levels confirm $22 target.
면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.